WMIF MAIN SITE

2024 COMING SOON

Past Forum 2022

Summary

The eight annual World Medical Innovation Forum was back in person in Boston.

This year, we gathered to discuss the extraordinary opportunities in gene and cell therapy and the profound impact they will have on medicine. In more than thirty sessions over the course of three days, Mass General Brigham’s Harvard faculty, industry experts and leading investors and entrepreneurs explored the technologies and challenges of gene and cell therapy as we continue to bring life-changing breakthroughs to our patients and millions around the world.

The World Medical Innovation Forum was established to reaffirm the importance of collaborative innovation—academia, industry and government working together to create solutions for medicine’s great challenges. Our goal is to provide actionable insights for Forum participants. We are grateful to the nearly 200 senior executives, investors, Harvard clinicians and investigators who shared their perspectives as speakers.

Speakers

Co-Founder, Candel Therapeutics

Principal Investigator, Ragon Institute, MGH; – Professor of Medicine, HMS

CMO and Head of R&D, Triplet Therapeutics, Inc.

Associate Bioengineer, BWH; – Associate Professor of Medicine, HMS

Chairman of the Board of Directors, Berlin Institute of Health at Charité (BIH)

CSO, Parkinson’s Foundation

Principal Investigator, Department of Neurosurgery, BWH; – Assistant Professor of Neurosurgery, HMS

Chief Preparedness and Continuity Officer, Mass General Brigham; – Associate Professor of Emergency Medicine, HMS

Managing Director, Healthcare Investment Banking, BofA Securities

Chief, Division of Renal Medicine, BWH; – Samuel A. Levine Distinguished Professor of Medicine and Constantine L. Hampers Distinguished Chair, HMS

CEO, Pfizer Inc.

President & CEO, Avidity Biosciences, Inc.

CEO, Amgen

Senior Writer, STAT

President, Mass General Hospital; – MGH Trustees Professor of Emergency Medicine, HMS

Director, Massachusetts Host-Microbiome Center, BWH; – Associate Professor of Pathology, HMS

CEO, Locanabio

Managing Director, Co-Head, North American Healthcare Investment Banking, Head of Life Sciences Investment Banking, BofA Securities

CEO, Rubius Therapeutics

Commissioner, US Food and Drug Administration

Chairman, Department of Neurosurgery, MGH; – William and Elizabeth Sweet Professor of Neurosurgery, HMS

CEO, ThermoFisher

President, Massachusetts, Bank of America

Medical Director of Kidney and Pancreas Transplantation, BWH; – Associate Professor of Medicine, HMS

Associate Scientist, Eaton-Peabody Laboratories, Mass Eye and Ear; – Associate Professor of Otolaryngology Head and Neck Surgery, HMS

Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH; – Harvey W. Cushing Professor of Neurosurgery, HMS

Assistant Professor of Neurosurgery, BWH, HMS

Partner, Lightspeed

Chief Innovation Officer, Mass General Brigham

CEO, Rett Syndrome Research Trust

Reporter, CNBC

Bertarelli Professor of Translational Medical Science, Neurobiology, HMS

Assistant in Neuroscience, Center for Genomic Medicine, MGH; – Assistant Professor of Neurology, HMS

CEO, CytoImmune

Chair, Department of Neurology, MGH; – Julieanne Dorn Professor of Neurology, HMS

Managing Director, Global Research, BofA Securities

Director, Center for Rare Neurological Diseases, MGH; – Associate Professor of Neurology, HMS

President & CEO, BlueRock Therapeutics

President & CEO, Bellicum

Chairman of the Board, Bank of America Europe

Chairman & CEO, Suffolk; – Chair, Brigham and Women’s Hospital

President & CEO, MeiraGTx

Partner, Atlas Venture

President, Novartis Gene Therapies

Clinical Director, Cellular Immunotherapy Program, MGH; – Assistant Professor of Medicine, HMS

Global Head of Life Sciences, Blackstone

VP, Head of Patient Advocacy, Solid Biosciences

Biopharma Equity Research Analyst, Bank of America

Chief Scientific Officer, Mass Eye and Ear; – Sir William Osler Professor of Ophthalmology, HMS

Chief of Pediatric Surgery, MGH; – Surgeon-in-Chief, MassGeneral for Children; – Marshall K. Bartlett Professor of Surgery, HMS

Director, Genomes2People Research Program, BWH; – Professor of Medicine, HMS

Assistant Investigator, Center for Genomic Medicine, MGH; – Assistant Professor of Neurology, HMS

Director, Chemical Neurobiology Laboratory, Center for Genomic Medicine, MGH; – Associate Professor of Neurology, HMS

Chairman & CEO, ElevateBio

Vice President, Global Research, BofA Securities

Chief Editor, Cell & Gene

Vice President, Global Research, BofA Securities

President & CEO, Caribou Biosciences

Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy, Bristol Myers Squibb

Director, Deep Brain Stimulation Program, MGH; – Assistant Professor of Neurology, HMS

President, Brigham and Women’s Hospital; – Executive Vice President, Mass General Brigham

CEO, GNS Healthcare

President Emerita, MIT

Director, Neuroregeneration Research Institute, McLean Hospital; – Professor of Neurology and Neuroscience, HMS

Principal Investigator, Center for Cancer Research, MGH; – Assistant Professor of Pathology, HMS

Robert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist, MGH; – Professor of Pathology, HMS

Richard W. Vague Professor in Immunotherapy, Director, Center for Cellular Immunotherapies, Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine

President, Board of Directors, National Tay Sachs and Allied Diseases; – Medical Geneticist, Associate Professor of Clinical Medicine, Penn Medicine

CEO, ROME Therapeutics

CEO, Verve Therapeutics

Co-Founder & CEO, Ginkgo Bioworks

Director, Molecular Neurobiology Laboratory, McLean; – Professor of Neuroscience and Psychiatry, HMS

Senior Vice President, Venture, Business Development and Licensing, Mass General Brigham

President & CEO, Mass General Brigham

President & Managing Partner, F-Prime Capital

Partner, Bain Capital Life Sciences

President, The Kraft Group; – Chairman, Board of Trustees, MGH

Associate Professor of Neurology, BWH, HMS

Portfolio Manager, Citadel

Chief, Division of Infectious Diseases, BWH; – Harriet Ryan Albee Professor of Medicine, HMS

Molecular Biologist, MGH; – Professor of Genetics, HMS

CEO, 2seventy bio

President & CEO, CAMP4 Therapeutics

Executive Chairman & Founder, Alexandria Real Estate Equities, Inc.

Chief, Division of Transplant Surgery, MGH; – Claude E. Welch Professor of Surgery, HMS

Director, Center for Biologics Evaluation and Research, FDA

Director, Cellular Immunotherapy Program, Cancer Center, MGH

Founding Partner, Founding Partner, Polaris Partners

Founder & CEO, Neurogene

Managing Director, Global Research, BofA Securities

President & CEO, California Institute for Regenerative Medicine

Instructor in Neurosurgery, BWH, HMS

CEO, Affinia Therapeutics

Chair & CEO, Bank of America

Managing Director & Head of Healthcare in Equity Capital Markets, BofA Securities

Mallinckrodt Professor of Genetics, Emeritus, HMS; – Executive Vice Chairman, Sana Biotechnology, Inc

Vice President Viral Vector Services, Thermo Fisher

Director, San Raffaele Telethon Institute for Gene Therapy

Managing Partner, Polaris Ventures

Medical Director, Cell Manipulation Core Facility, Technical Director, Immune Effector Cell Therapy Program, DFCI; – Assistant Professor, HMS

Executive Director, Mucolipidosis Type IV (ML4) Foundation

COO, ElevateBio BaseCamp, ElevateBio

CMO, Vigil Neuroscience

Neurosurgeon and Principal Investigator, BWH; – Assistant Professor of Neurosurgery, HMS

President, R&D, Takeda

Director, Vaccine and Immunotherapy Center, MGH; – Professor of Medicine, HMS

Professor, Neurology, Ann Romney Center for Neurologic Diseases, BWH; – Kuchroo Weiner Distinguished Professor of Neuroimmunology, BWH

CEO & Co-Founder, Fractyl Health

Co-Director of Neuroscience, Associate Geneticist in Neurology, MGH; – Professor of Neurology, HMS

CMO, Abata Therapeutics; – Venture Partner, Third Rock Ventures

Senior Vice President, Clinical Development, PACT Pharma

VP, Head of New Platforms, Ophthalmology and Hemophilia, Bayer

VP Head of Translational Medicine, Syncopation Life Sciences

Venture Partner, GV

Director, Global Research, BofA Securities

EVP, Chief of Cell & Gene Therapies and VCGT Site Head, Vertex Pharmaceuticals

Chairman of the Board, Vir Biotechnology – Chairman, Denali Therapeutics

Director, Center for Regenerative Medicine, MGH; – Gerald and Darlene Jordan Professor of Medicine, HMS

Neurosurgeon, MGH; – Assistant Professor of Neurosurgery, HMS

Director, Cardiovascular Genetics Center, BWH; – Smith Professor of Medicine & Genetics, HMS

Executive Vice President, Chief Scientific Officer, Intellia Therapeutics

President & CEO, Garuda Therapeutics

Vice Chairman of Research, Department of Neurosurgery, BWH; – Professor, HMS

Institute Professor and Professor of Biology, Koch Institute for Integrative Cancer Research at MIT; – Co-Founder, Alnylam Pharmaceuticals, Inc.

Former Director, National Cancer Institute

CEO, Kite, a Gilead Company

CMO, BridgeBio Gene Therapy

Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation

Associate Chief, Infection Control Unit, MGH; – Associate Professor of Medicine, HMS

CEO, National Resilience, Inc.

Senior Vice President, Chief Scientific and Medical Officer, Eli Lilly and Company

Scientific Director and Elizabeth G. Riley and Daniel E. Smith Jr. Endowed Chair, Mass General Research Institute; – Professor, Neurology, HMS

Co-CEO, Thomas H. Lee Partners; – Chairman of the Board, Mass General Brigham

CEO, Chroma Medicine

HHMI Investigator, F.M. Kirby Neurobiology Research Program, Boston Children’s Hospital; – Associate Professor of Neurology, HMS

Vice President, Equity Research, BofA Securities

Director, Experimental Therapeutics Unit, Director, Viral Vector Core, MGH; – Professor of Neurology, HMS

Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH; – Joseph P. and Rose F. Kennedy Professor of Neurology, HMS

Chief Academic Officer, Mass General Brigham

Grousbeck Associate Professor in Gene Therapy, Mass General Brigham (on leave)

Associate Director of the Retina Service, Mass Eye and Ear; – Solman and Libe Friedman Professor of Ophthalmology, Co-Director Ocular Regenerative Medical Institute, HMS

Chairman & CEO, Walking Fish Therapeutics

Anchor/Reporter, Bloomberg

Director, Minda de Gunzburg Center for Retinal Regeneration, Associate Scientist, Schepens Eye Research Institute, Mass Eye and Ear; – Associate Professor of Ophthalmology, Co-Director, Ocular Regenerative Medicine Institute, HMS

Professor, Whitehead Institute, MIT

Principal Investigator, Grousbeck Gene Therapy Center, Mass Eye and Ear; – Instructor in Ophthalmology, HMS

Vice President, Global Research, BofA Securities

CEO, Landmark Bio

Day One: Monday, May 2, 2022

First Look: 8 rapid fire presentations on Mass General Brigham’s new GCT technologies

    • Moderator: Meredith Fisher, PhD, Partner, Mass General Brigham Ventures
    • Moderator: Roger Kitterman, VP, Mass General Brigham Ventures

    Presenters:

    • Bakhos Tannous, PhD, Director, Experimental Therapeutics Unit, Director, Viral Vector Core, MGH; Professor of Neurology, HMS
    • Vijaya Ramesh, PhD, Co-Director of Neuroscience, Associate Geneticist in Neurology, MGH; Professor of Neurology, HMS
    • Anna Krichevsky, PhD, Associate Professor of Neurology, BWH, HMS
    • Nerea Zabaleta, PhD, Principal Investigator, Grousbeck Gene Therapy Center, Mass Eye and Ear; Instructor in Ophthalmology, HMS
    • Francisco Quintana, PhD, Professor, Neurology, Ann Romney Center for Neurologic Diseases, BWH; Kuchroo Weiner Distinguished Professor of Neuroimmunology, BWH
    • Stephen Haggarty, PhD, Director, Chemical Neurobiology Laboratory, Center for Genomic Medicine, MGH; Associate Professor of Neurology, HMS
    • Michael Young, PhD, Director, Minda de Gunzburg Center for Retinal Regeneration, Associate Scientist, Schepens Eye Research Institute, Mass Eye and Ear; Associate Professor of Ophthalmology, Co-Director, Ocular Regenerative Medicine Institute, HMS
    • Max Jan, MD, PhD, Principal Investigator, Center for Cancer Research, MGH; Assistant Professor of Pathology, HMS
Watch Panel Here

First Look: 8 rapid fire presentations on Mass General Brigham’s new GCT technologies

    • Moderator: Meredith Fisher, PhD, Partner, Mass General Brigham Ventures
    • Moderator: Roger Kitterman, VP, Mass General Brigham Ventures

    Presenters:

    • Choi-Fong Cho, PhD, Assistant Professor of Neurosurgery, BWH, HMS
    • Yulia Grishchuk, PhD, Assistant Investigator, Center for Genomic Medicine, MGH; Assistant Professor of Neurology, HMS
    • Lynn Bry, MD, PhD, Director, Massachusetts Host-Microbiome Center, BWH; Associate Professor of Pathology, HMS
    • David Corey, PhD, Bertarelli Professor of Translational Medical Science, Neurobiology, HMS
    • Anil Chandraker, MD, Medical Director of Kidney and Pancreas Transplantation, BWH; Associate Professor of Medicine, HMS
    • Ole Isacson, MD, PhD, Director, Neuroregeneration Research Institute, McLean; Professor of Neurology & Neuroscience, HMS
    • Marco Mineo, PhD, Instructor in Neurosurgery, BWH, HMS
    • Susan Cotman, PhD, Assistant in Neuroscience, Center for Genomic Medicine, MGH; Assistant Professor of Neurology, HMS
Watch Panel Here

THE DR. IS IN | Gene and Epigenetic Editing in the Development of Treatment for Deafness

  • Moderator: Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
  • Albert Edge, PhD, Eaton Peabody Professor of Otolaryngology, HMS, Mass Eye and Ear
Watch Panel Here

THE DR. IS IN | Single Gene Correction in the Brain: Delivering Where it Matters Most

  • Moderator: Tazeen Ahmad, Managing Director, Global Research, BofA Securities
  • Florian Eichler, MD, Director, Center for Rare Neurological Diseases, MGH; Associate Professor of Neurology, HMS
Watch Panel Here

THE DR. IS IN | Repair, Replace, Regrow: The Advancement of Regenerative Medicine

  • Moderator: Jason Zemansky, PhD, Vice President, Global Research, BofA Securities
  • Joseph Bonventre, MD, PhD, Chief, Division of Renal Medicine, BWH; Samuel A. Levine Distinguished Professor of Medicine and Constantine L. Hampers Distinguished Chair, HMS
  • David Scadden, MD, Director, Center for Regenerative Medicine, MGH; Gerald and Darlene Jordan Professor of Medicine, HMS
Watch Panel Here

THE DR. IS IN | Smart Materials: Non-viral Vectors for Gene Therapy

  • Moderator: Alec Stranahan, PhD, Vice President, Equity Research, BofA Securities
  • Natalie Artzi, PhD, Assistant Professor of Medicine, HMS
Watch Panel Here

THE DR. IS IN | Newborn Sequencing and Prevention of Rare Diseases: A New Public Health and Biopharma Challenge

  • Moderator: Jason Gerberry, Managing Director, Global Research, BofA Securities
  • Robert Green, MD, Director, Genomes2People Research Program, BWH; Professor of Medicine, HMS
  • Adam Shaywitz, MD, PhD, CMO, BridgeBio Gene Therapy
Watch Panel Here

THE DR. IS IN | Newborn Sequencing and Prevention of Rare Diseases: A New Public Health and Biopharma Challenge

  • Moderator: Jason Gerberry, Managing Director, Global Research, BofA Securities
  • Robert Green, MD, Director, Genomes2People Research Program, BWH; Professor of Medicine, HMS
  • Adam Shaywitz, MD, PhD, CMO, BridgeBio Gene Therapy
Watch Panel Here

THE DR. IS IN | Leveraging Novel Mechanisms for Accelerated Vaccine and Immunotherapy Development

  • Moderator: Alexandria Hammond, PhD, Associate, Global Research, BofA Securities
  • Mark Poznansky, MD, PhD, Director, Vaccine and Immunotherapy Center, MGH; Professor of Medicine, HMS
Watch Panel Here

Opening Remarks

  • Introducer: Scott Sperling, Co-Chief Executive Officer, Thomas H. Lee Partners; Chairman of the Board of Directors, Mass General Brigham
  • Anne Klibanski, MD, President & CEO, Mass General Brigham; Laurie Carrol Guthart Professor of Medicine, HMS
  • Brian Moynihan, Chair & CEO, Bank of America
Watch Panel Here

Co-Chair Kick Off

  • Moderator: Susan Hockfield, PhD, President Emerita, MIT
  • Miceal Chamberlain, President of Massachusetts, Northeast Region Executive, Bank of America
  • Marcela Maus, MD, PhD, Director, Cellular Immunotherapy Program, Cancer Center, MGH; Associate Professor, Medicine, HMS
  • Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
  • Ravi Thadhani, MD, Chief Academic Officer, Mass General Brigham
Watch Panel Here

GCT’s Historic Potential | Priorities and Trade Offs

  • Moderator: Jean-François Formela, MD, Partner, Atlas Venture
  • Pablo Cagnoni, MD, CEO, Rubius Therapeutics
  • Kristen Hege, MD, Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy, Bristol Myers Squibb
  • Andrew Plump, MD, PhD, President, R&D, Takeda
    Catherine Stehman-Breen, MD, CEO, Chroma Medicine
Watch Panel Here

Manufacturing | Process Control

  • Moderator: John Bishai, PhD, Managing Director, Global Investment Banking, BofA Securities
  • Christopher Murphy, Vice President Viral Vector Services, Thermo Fisher
  • Michael Paglia, COO, ElevateBio BaseCamp, ElevateBio
  • Rahul Singhvi, ScD, CEO, National Resilience, Inc.
  • Ran Zheng, CEO, Landmark Bio
Watch Panel Here

FIRESIDE | Regulatory Perspectives on Gene and Cell Therapy: Past Lessons, Current Challenges, Future Directions

  • Moderator: Luk Vandenberghe, PhD, Grousbeck Associate Professor in Gene Therapy, Mass General Brigham
    Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, FDA
Watch Panel Here

Clinical GCT Trial Design | Regulatory | Strategy, Innovation and Future Direction | Risk vs Hype

  • Moderator: Angela Shen, MD, Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation
  • Laura Aguilar, MD, PhD, Co-Founder, Candel Therapeutics
  • Matthew Frigault, MD, Clinical Director, Cellular Immunotherapy Program, MGH; Assistant Professor of Medicine, HMS
  • Arati Rao, MD, Senior Vice President, Clinical Development, PACT Pharma
  • John Rossi, VP Head of Translational Medicine, Syncopation Life Sciences
Watch Panel Here

FIRESIDE | mRNA Opportunities: Lessons Learned, Priorities, and the Future of GCT

  • Moderator: Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
  • Albert Bourla, PhD, CEO, Pfizer Inc.
Watch Panel Here

Day Two: Tuesday, May 3, 2022

FIRESIDE | Robert Califf, MD, Commissioner Food and Drugs, FDA

  • Moderator: Tazeen Ahmad, Managing Director, Global Research, BofA Securities
  • Moderator: J. Keith Joung, MD, PhD, Robert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist, MGH; Professor of Pathology, HMS
  • Robert Califf, MD, Commissioner of Food and Drugs, US Food and Drug Administration
Watch Panel Here

The Grand Challenge of Widespread GCT Patient Benefits

  • Moderator: Susan Hockfield, PhD, President Emerita and Professor of Neuroscience, MIT
  • Nino Chiocca, MD, PhD, Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH; Harvey W. Cushing Professor of Neurosurgery, HMS
  • Susan Slaugenhaupt, PhD, Scientific Director and Elizabeth G. Riley and Daniel E. Smith Jr., Endowed Chair, Mass General Research Institute; Professor, Neurology, HMS
  • Ravi Thadhani, MD, CAO, Mass General Brigham; Professor, Medicine and Faculty Dean, HMS
  • Luk Vandenberghe, PhD, Grousbeck Family Chair, Gene Therapy; MEE Associate Professor, Ophthalmology, HMS
Watch Panel Here

Living with COVID | Lessons Learned and Looking Ahead

  • Introducer: Jonathan Kraft, President, The Kraft Group; Chairman of the Board of Trustees, MGH
  • Moderator: David Brown, MD, President, Massachusetts General Hospital; Executive Vice President, Mass General Brigham
  • Paul Biddinger, MD, Chief Preparedness and Continuity Officer, Mass General Brigham; Associate Professor of Emergency Medicine, HMS
  • Helen Branswell, Senior Writer, STAT
  • Daniel Kuritzkes, MD, Chief, Division of Infectious Diseases, BWH; Harriet Ryan Albee Professor of Medicine, HMS
  • Erica Shenoy, MD, PhD, Associate Chief, Infection Control Unit, MGH; Associate Professor of Medicine, HMS
Watch Panel Here

The Global Biotech Epicenter | New England Now and in 2030

  • Moderator: Anne Finucane, Chairman of the Board, Bank of America Europe
  • Seth Ettenberg, PhD, President & CEO, BlueRock Therapeutics
  • Joel Marcus, Executive Chairman & Founder, Alexandria Real Estate Equities, Inc.
  • Terry McGuire, Founding Partner, Polaris Partners
  • Vicki Sato, PhD, Chairman of the Board, Vir Biotechnology; Chairman, Denali Therapeutics
  • Phillip Sharp, PhD, Institute Professor and Professor of Biology, Koch Institute for Integrative Cancer Research at MIT; Co-Founder, Alnylam Pharmaceuticals, Inc.
Watch Panel Here

The Patient Experience

  • Moderator: Merit Cudkowicz, MD, Chair, Dept of Neurology, MGH; Julieanne Dorn Professor of Neurology, HMS
  • James Beck, PhD, CSO, Parkinson’s Foundation
  • Monica Coenraads, CEO, Rett Syndrome Research Trust
  • Annie Ganot, VP, Head of Patient Advocacy, Solid Biosciences
  • Staci Kallish, DO, President, Board of Directors, National Tay Sachs and Allied Diseases; Medical Geneticist, Associate Professor of Clinical Medicine, Penn Medicine
  • Rebecca Oberman, PhD, Executive Director, Mucolipidosis Type IV (ML4) Foundation
Watch Panel Here

FIRESIDE | Meeting the Moment: The Next Wave of Innovation in Cancer and Cardiology

  • Moderator: Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
  • Robert Bradway, CEO, Amgen
Watch Panel Here

First Look Award Presentation

  • Presenter: Miceal Chamberlain, President of Massachusetts, Northeast Region Executive, Bank of America
  • Presenter: Nino Chiocca, MD, PhD, Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH; Harvey W. Cushing Professor of Neurosurgery, HMS
Watch Panel Here

IDG Award Announcement

Watch Panel Here

THE DR. IS IN | Personalizing Cancer Care through RNA Therapies

  • Moderator: Jason Gerberry, Managing Director, Global Research, BofA Securities
  • Pierpaolo Peruzzi, MD, PhD, Neurosurgeon and Principal Investigator, BWH; Assistant Professor of Neurosurgery, HMS
Watch Panel Here

THE DR. IS IN | Designing for Success: Clinical Trial Approaches for Rare and Ultra-Rare Diseases

  • Moderator: Tazeen Ahmad, Managing Director, Global Research, BofA Securities
  • Demetrios Vavvas, MD, PhD, Associate Director of the Retina Service, Mass Eye and Ear; Solman and Libe Friedman Professor of Ophthalmology, Co-Director Ocular Regenerative Medical Institute, HMS
Watch Panel Here

THE DR. IS IN | A New Hope: Cell Therapy and Transplantation for Parkinson’s Disease

  • Moderator: Greg Harrison, Vice President, Global Research, BofA Securities
  • Bob Carter, MD, PhD, Chairman, Department of Neurosurgery, MGH; William and Elizabeth Sweet Professor of Neurosurgery, HMS
  • Todd Herrington, MD, PhD, Director, Deep Brain Stimulation Program, MGH; Assistant Professor of Neurology, HMS
  • Kwang-Soo Kim, PhD, Director, Molecular Neurobiology Laboratory, McLean; Professor of Neuroscience and Psychiatry, HMS
  • Jeffrey Schweitzer, MD, PhD, Neurosurgeon, MGH; Assistant Professor of Neurosurgery, HMS
Watch Panel Here

THE DR. IS IN | The Inner Workings of Gene Therapy Manufacturing

  • Moderator: Michael Ryskin, Director, Global Research, BofA Securities
  • Sarah Nikiforow, MD, PhD, Medical Director, Cell Manipulation Core Facility, Technical Director, Immune Effector Cell Therapy Program, DFCI; Assistant Professor, HMS
Watch Panel Here

THE DR. IS IN | The Road Ahead: Regulatory Challenges for Gene and Cell Therapy

  • Moderator: Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
  • Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, FDA
Watch Panel Here

THE DR. IS IN | The Mysterious Dark Genome

  • Moderator: Angela Shen, MD, Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation
  • Moderator: Richard Young, PhD, Professor, Whitehead Institute, MIT
  • Rosana Kapeller, MD, PhD, Co-Founder, President & CEO, ROME Therapeutics
  • Josh Mandel-Brehm, President & CEO, CAMP4 Therapeutics
  • Amir Nashat, PhD, Managing Partner, Polaris Ventures
  • Issi Rozen, Venture Partner, GV
Watch Panel Here

Capital Formation | Shaping Innovation

  • Moderator: Greg Butz, Managing Director, Head of Life Sciences Investment Banking, BofA Securities
  • Moderator: Sumit Mukherjee, Managing Director & Head of Healthcare in Equity Capital Markets, BofA Securities
  • Shelley Chu, MD, PhD, Partner, Lightspeed
  • Stephen Knight, MD, President & Managing Partner, F-Prime Capital
  • Adam Koppel, MD, PhD, Managing Director, Bain Capital Life Sciences
  • Daniel Krizek, Portfolio Manager, Citadel
Watch Panel Here

FIRESIDE | Ending Cancer as We Know It: The Game Changing Potential of GCT

  • Moderator: Erin Harris, Chief Editor, Cell & Gene
  • David Scadden, MD, Director, Center for Regenerative Medicine, MGH; Gerald and Darlene Jordan Professor of Medicine, HMS
  • Norman Sharpless, MD, Former Director, National Cancer Institute
Watch Panel Here

FIRESIDE | Vision and Execution: Curing Disease with Cell Therapies

  • Moderator: Marcela Maus, MD, PhD, Director, Cellular Immunotherapy Program, Cancer Center, MGH
    Associate Professor, Medicine, HMS
  • Moderator: Ravi Thadhani, MD, Chief Academic Officer, Mass General Brigham
  • Carl June, MD, Richard W. Vague Professor in Immunotherapy, Director, Center for Cellular Immunotherapies, Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine
Watch Panel Here

GCT Development Centers | Academia’s Unique Contribution

  • Moderator: Ravi Thadhani, MD, Chief Academic Officer, Mass General Brigham
  • Carl June, MD, Richard W. Vague Professor in Immunotherapy, Director, Center for Cellular Immunotherapies, Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine
  • Maria Millan, MD, President & CEO, California Institute for Regenerative Medicine
  • Richard Mulligan, PhD, Mallinckrodt Professor of Genetics, Emeritus, HMS; Executive Vice Chairman, Sana Biotechnology, Inc
  • Norman Sharpless, MD, Former Director, National Cancer Institute
Watch Panel Here

FIRESIDE | Marc Casper

  • Moderator: Derik de Bruin, PhD, Managing Director, Global Research, BofA Securities
  • Marc Casper, CEO, ThermoFisher
Watch Panel Here

Gene and Cell Therapy | The World Speaks

  • Moderator: Christine Fox, President, Novartis Gene Therapies
  • Christopher Baum, MD, Chairman of the Board of Directors, Berlin Institute of Health at Charité (BIH)
  • Nicholas Galakatos, PhD, Global Head of Life Sciences, Blackstone
  • Luigi Naldini, MD, PhD, Director, San Raffaele Telethon Institute for Gene Therapy
  • Kendra Rose, PhD, VP, Head of New Platforms, Ophthalmology and Hemophilia, Bayer
Watch Panel Here

Control or Mitigation of the Effects of Chronic Neuroinflammation

  • Moderator: Ole Isacson, MD, PhD, Director, Neuroregeneration Research Institute, McLean; Professor of Neurology & Neuroscience, HMS
  • Colin Hill, CEO, GNS Healthcare
  • Spyros Papapetropoulos, MD, PhD, CMO, Vigil Neuroscience
  • Richard Ransohoff, MD, CMO, Abata Therapeutics; Venture Partner, Third Rock Ventures
  • Beth Stevens, PhD, HHMI Investigator, F.M. Kirby Neurobiology Research Program, Boston Children’s Hospital; Associate Professor of Neurology, HMS
  • Rudolph Tanzi, PhD, Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH; Joseph P. and Rose F. Kennedy Professor of Neurology, HMS
Watch Panel Here

Day Three: Wednesday, May 4, 2022

The Cell Therapy Landscape | CAR-T to Stem Cells

  • Moderator: Marcela Maus, MD, PhD, Director, Cellular Immunotherapy Program, Cancer Center, MGH; Associate Professor, Medicine, HMS
  • Christina Coughlin, MD, PhD, CEO, CytoImmune
  • Rachel Haurwitz, PhD, President & CEO, Caribou Biosciences
  • Nick Leschly, CEO, 2seventy bio
  • Dhvanit Shah, PhD, President & CEO, Garuda Therapeutics
  • Rusty Williams, MD, PhD, Chairman & CEO, Walking Fish Therapeutics
Watch Panel Here

Disrupting Interventions

  • Introducer: John Fish, Chairman & CEO, Suffolk; Chair, Brigham and Women’s Hospital
  • Moderator: Robert Higgins, MD, President, Brigham and Women’s Hospital; Executive Vice President, Mass General Brigham
  • Irina Antonijevic, MD, PhD, CMO and Head of R&D, Triplet Therapeutics, Inc.
  • Rachel McMinn, PhD, Founder & CEO, Neurogene
  • Harith Rajagopalan, MD, PhD, CEO & Co-Founder, Fractyl Health
  • Bastiano Sanna, PhD, EVP, Chief of Cell & Gene Therapies and VCGT Site Head, Vertex Pharmaceuticals
  • Jeffrey Schweitzer, MD, PhD, Neurosurgeon, MGH; Assistant Professor of Neurosurgery, HMS
Watch Panel Here

FIRESIDE | Reimagining GCT Production

  • Moderator: Derik de Bruin, PhD, Managing Director, Global Research, BofA Securities
  • Jason Kelly, PhD, Co-Founder & CEO, Ginkgo Bioworks
Watch Panel Here

Gene and Cell Therapy Safety | Enduring Framework Required

  • Moderator: Christine Seidman, MD, Director, Cardiovascular Genetics Center, BWH; Smith Professor of Medicine & Genetics, HMS
  • Rick Fair, President & CEO, Bellicum
  • Alexandria Forbes, PhD, President & CEO, MeiraGTx
  • Sekar Kathiresan, MD, CEO, Verve Therapeutics
    Rick Modi, CEO, Affinia Therapeutics

RNA Therapeutics | Lessons Learned

  • Moderator: Janet Wu, Anchor/Reporter, Bloomberg
  • Sarah Boyce, President & CEO, Avidity Biosciences, Inc.
  • Jim Burns, PhD, CEO, Locanabio
  • Jeannie Lee, MD, PhD, Molecular Biologist, MGH; Professor of Genetics, HMS
  • Laura Sepp-Lorenzino, PhD, Chief Scientific Officer, Executive Vice President, Intellia Therapeutics
Watch Panel Here

Disruptive Dozen: 12 Technologies That Will Reinvent GCT in the Next Five Years

  • Moderator: Nino Chiocca, MD, PhD, Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH; Harvey W. Cushing Professor of Neurosurgery, HMS
  • Moderator: Susan Slaugenhaupt, PhD, Scientific Director and Elizabeth G. Riley and Daniel E. Smith Jr. Endowed Chair, Mass General Research Institute; Professor, Neurology, HMS
  • Moderator: Ravi Thadhani, MD, Chief Academic Officer, Mass General Brigham
  • Galit Alter, PhD, Principal Investigator, Ragon Institute, MGH; Professor of Medicine, HMS
  • Natalie Artzi, PhD, Assistant Professor of Medicine, HMS
  • Fengfeng Bei, PhD, Principal Investigator, Department of Neurosurgery, BWH; Assistant Professor of Neurosurgery, HMS
  • Zheng-Yi Chen, DPhil, Associate Scientist, Eaton-Peabody Laboratories, Mass Eye and Ear; Associate Professor of Otolaryngology Head and Neck Surgery, HMS
  • Matthew Frigault, MD, Clinical Director, Cellular Immunotherapy Program, MGH; Assistant Professor of Medicine, HMS
  • Michael Gilmore, PhD, Chief Scientific Officer, Mass Eye and Ear; Sir William Osler Professor of Ophthalmology, HMS
  • Allan Goldstein, MD, Chief of Pediatric Surgery, MGH; Surgeon-in-Chief, MassGeneral for Children
  • Anna Krichevsky, PhD, Associate Professor of Neurology, BWH, HMS
  • Jeannie Lee, MD, PhD, Molecular Biologist, MGH; Professor of Genetics, HMS
  • James Markmann, MD, PhD, Chief, Division of Transplant Surgery, MGH; Claude E. Welch Professor of Surgery, HMS
  • Khalid Shah, PhD, Vice Chairman of Research, Department of Neurosurgery, BWH; Professor, HMS
  • Demetrios Vavvas, MD, PhD, Associate Director of the Retina Service, Mass Eye and Ear; Solman and Libe Friedman Professor of Ophthalmology, Co-Director Ocular Regenerative Medical Institute, HMS
Watch Panel Here

Sponsors